He Xue, Hu Bin, Zhang Yingzi, Liu Fei, Li Qiuyu, Zheng Chen, Shen Junjie, Yang Zhi, Wang Jingjing, Ma Daqing, Qian Cheng, Lu Meiping, Mao Jianhua
Department of Nephrology, Children's Hospital, Zhejiang University School of Medicine, National clinical research center for child health, Hangzhou 310052, China.
Department of Allergy Immunology and Rheumatology, Children's Hospital, Zhejiang University School of Medicine, National clinical research center for child health, Hangzhou 310052, China.
Autoimmun Rev. 2025 Jan 3;24(1):103692. doi: 10.1016/j.autrev.2024.103692. Epub 2024 Nov 17.
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for treating autoimmune diseases, particularly in systemic lupus erythematosus (SLE). However, CAR T-cell therapy for pediatric patients with SLE remains unexplored. Herein, we present a compelling investigation of two pediatric patients with refractory SLE who underwent infusion of CD19-targeted CAR T-cells. Patients 1 and 2 tolerated the CAR T-cell therapy well, which demonstrated remarkable efficacy after five and four months, respectively.
嵌合抗原受体（CAR）T细胞疗法已成为治疗自身免疫性疾病的一种有前景的策略，尤其是在系统性红斑狼疮（SLE）方面。然而，针对儿童SLE患者的CAR T细胞疗法仍未得到探索。在此，我们对两名难治性SLE儿童患者进行了引人注目的研究，他们接受了靶向CD19的CAR T细胞输注。患者1和患者2对CAR T细胞疗法耐受性良好，分别在五个月和四个月后显示出显著疗效。
